Industry: Technology for SPECT-guided CRT

This early-stage medical technology company is advancing techniques in medical imaging for heart failure patients. The advanced techniques could improve the long-term results of cardiac resynchronization therapy devices, delivering better health outcomes.
Around 670,000 patients are diagnosed with heart failure each year. Cardiac resynchronization therapy (CRT) is the standard treatment for moderate and severe cases, with more than 60,000 CRT implantations each year. Unfortunately, despite the costliness of the procedure, about 30 to 40 percent of patients who receive a CRT implantation do not see noticeable health improvement.
Using SPECT-guided CRT technology, physicians could optimize the left-ventricular lead placement of the CRT device. Guided implantation could offer significant benefits over non-guided implantation and increase the effectiveness of CRT. 

Back to companies